Description

  Amgen: How Its $3.5 Billion Acquisition & Its High-Stakes Drug Pipeline Are Reshaping Its Growth Strategy

Amgen Inc. highlighted substantial achievements and growth potential for 2024 while outlining some challenges and strategies moving forward. The company’s financial results reflected its success across various therapeutic areas, despite facing pricing pressures and patent expirations. Revenue for the full year of 2024 reached $33.4 billion, reflecting a significant 19% increase year-over-year, driven mainly by a 23% volume increase across products. Amgen’s diverse portfolio saw an impressive number of ten products achieving double-digit growth and 21 products delivering record sales. The company’s continued growth trajectory is supported by major products like Repatha, EVENITY, TEZSPIRE, and promising oncology offerings, including BLINCYTO and IMDELLTRA.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!